Skip to main content

Hyperalgesia clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for
  • Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate whether using ultra-low dose naloxone, an opioid antagonist, has the potential to block remifentanil-induced hyperalgesia and tolerance following surgery. There are 3 study groups: (1) low dose remifentanil (LO, 0.1 micrograms/kg/mL), (2) high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL), or (3) high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone). The hypothesis of the study is that occurrence of remifentanil-induced hyperalgesia (low score in mechanical pain threshold) in the HN group will be lower than in the HI group.

    Orange, California

Our lead scientists for Hyperalgesia research studies include .

Last updated: